SEO URLwww.firestrike.ai/deals/corstasis-esperion-acquisition-2026
acquisitionAnnounced · Mar 3, 2026biopharmaSource · CredibleArticle · Factual
Esperion acquires Corstasis
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$75M
Target
Corstasis
Acquirer
Esperion
Full Acquisition
Status
Announced
Esperion agreed to acquire Corstasis. Reported deal value: $75M. Status: Announced. Sector: biopharma. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.
Sign in or Register Healthcare PE - backed Esperion to acquire biopharma firm Corstasis for $ 75m upfront Corstasis shareholders also will be eligible to receive a total of up to an additional $180 million upon the attainment of certain regulatory and commercial milestones
Deal timeline
Announced
Mar 3, 2026 · pehub.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biopharma with a reported deal value of $75M. Figures and status may change as sources update.
Sources: pehub.com · Primary article · FireStrike proprietary index